NASDAQ Healthcare Biotechnology ENTA

Enanta Pharmaceuticals, Inc.

$ 12.66 0.16 %

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

CEO: Jay R. Luly - https://www.enanta.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$48.2 280.73 %

Recommandation

Buy

DCF

$ -60.97

Loading data...

ENTA vs S&P500

Loading data...

No data available.

Quick ratio

3.84

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-4.87

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.60

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-64.04 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-19.90 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

6.80

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.60

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-0.45

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
-0.84 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.75 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.59 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.